Seizure control and pregnancy outcomes in Chinese women with epilepsy: A prospective multicenter cohort study
- PMID: 39931893
- DOI: 10.1111/epi.18294
Seizure control and pregnancy outcomes in Chinese women with epilepsy: A prospective multicenter cohort study
Abstract
Objective: Data on seizure and pregnancy outcomes in Asian women with epilepsy are limited. We used a Chinese pregnancy registry to assess the impact of seizures and antiseizure medications (ASMs) on pregnant women with epilepsy and their children.
Methods: This is an ongoing prospective multicenter study of pregnant women with epilepsy that has been running since 2012. Eligible participants were consecutively enrolled and had multiple follow-ups up to one year after delivery. We assessed ASM use and seizure frequency during pregnancy to establish potential effects on the mothers and infants and to identify relevant correlations. Descriptive analysis was used to estimate proportions. Logistic regression was used to identify the relevant risk factors and correlations.
Results: Of 1907 potentially eligible pregnancies, we included 1763 in 1483 women with known outcomes from January 2012 to February 2022. There were 1278 completed pregnancies, resulting in 1270 live births. Tonic-clonic seizures occurred in fewer than one-third of pregnancies in each trimester. Compared with baseline, seizure frequency remained relatively stable throughout approximately two-thirds of the pregnancies. The majority were on ASM, with levetiracetam (39%), oxcarbazepine (19%), and lamotrigine (17.5%) being the most commonly used. In contrast, only 14.2% of pregnancies were exposed to valproate (VPA). There was a declining trend in treatment adjustments over the course of the pregnancy, with most changes occurring in the first trimester. The incidence of major congenital malformation (MCM) was 4.4%, with cardiogenic and orofacial anomalies being the most common. VPA use (p < .001), lack of folic acid use (p = .009), positive family history of MCM (p = .006), and topiramate (TPM) use (p = .04) were the most important predictors of MCM.
Significance: Seizure control remained stable for the majority of women with epilepsy throughout pregnancy. Family history of MCM, VPA use, TPM use, and not taking folic acid were strong predictors of MCM in infants born to women with epilepsy.
Keywords: West China Registry of Pregnancy in Epilepsy; antiseizure medications; malformation; pregnancy registry; seizure frequency; women with epilepsy.
© 2025 International League Against Epilepsy.
References
REFERENCES
-
- Borthen I, Eide MG, Daltveit AK, Gilhus NE. Obstetric outcome in women with epilepsy: a hospital‐based, retrospective study. BJOG. 2011;118(8):956–965.
-
- Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton‐Smith J, et al. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology. 2012;78(16):1207–1214.
-
- Campbell E, Kennedy F, Russell A, Smithson WH, Parsons L, Morrison PJ, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland epilepsy and pregnancy registers. J Neurol Neurosurg Psychiatry. 2014;85(9):1029–1034.
-
- Razaz N, Tomson T, Wikström A‐K, Cnattingius S. Association between pregnancy and perinatal outcomes among women with epilepsy. JAMA Neurol. 2017;74:983–991.
-
- Viale L, Allotey J, Cheong‐See F, Arroyo‐Manzano D, Mccorry D, Bagary M, et al. Epilepsy in pregnancy and reproductive outcomes: a systematic review and meta‐analysis. Lancet. 2015;386(16):1845–1852.
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- 2022NSFSC1488/Natural Science Foundation of Sichuan Province
- HXHL20004/The West China Nursing Discipline Development Special Fund Project, Sichuan University
- ZYJC21001/1.3.5 project for disciplines of excellence and Brain Science project of West China Hospital, Sichuan University
- 2021YFC2401201/National Key Research and Development Program of China
- 2021YFC2401204/National Key Research and Development Program of China
- ZYGD20011/1.3.5 Talent Excellence Development Project - West China Hospital of Sichuan University
- ZYGD22003/1.3.5 Talent Excellence Development Project - West China Hospital of Sichuan University
- ZYGD23032/1.3.5 Talent Excellence Development Project - West China Hospital of Sichuan University
- 2019YFH0196/Sichuan Province Science and Technology Support Program
- 2023YFQ0109/Sichuan Province Science and Technology Support Program
- 81871017/National Natural Science Foundation of China
- 81901327/National Natural Science Foundation of China
- U21A20393/National Natural Science Foundation of China